News

Ilaprazole raw materials and enteric-coated tablets were developed by Korea's Yuhan Corporation in 2001, and the domestic Lizhu Group introduced the compound technology from this company in 2002, subsequently applying for research and development. It was approved for market release in December 2007 under the brand name Yilian, marking its global debut and being the only product in the domestic market.

Peptic ulcer disease is a common chronic condition of the digestive system, characterized by ease of diagnosis and treatment, but also a tendency for recurrence. There are various treatment options available, including antacids, gastric mucosal protectants, H2 receptor antagonists, proton pump inhibitors (PPIs), and traditional Chinese medicine. Among these, PPIs are currently the most potent acid suppressants, with the best clinical efficacy and the widest application, holding over 90% of the market share.

Influenza is a global public health issue, causing a large number of infections and even deaths each year. Oseltamivir phosphate, as a special-effect drug for the treatment and prevention of influenza, has a huge market demand and broad development prospects. The frequent occurrence of public health events has further expanded the anti-influenza drug market.

Oseltamivir phosphate is an anti-influenza virus medication that belongs to the class of neuraminidase inhibitors. It effectively inhibits the replication and transmission of influenza viruses. By suppressing the activity of neuraminidase in influenza viruses, it prevents the release of viruses from infected cells, thereby reducing the spread of viruses within the body.

As an industry leader, HRD Pharm invested 250 million RMB to build a national chemical factory covering an area of about 60 acres, with 6 GMP standard production workshops and an independent R&D team of 50 people. 

High standards, high-quality outcomes is the cornerstone of HRD Pharm’s operations. The company strictly adheres to international standards and regulatory requirements, ensuring that every product that leaves its facilities is of the highest quality.

ZHUHAI HRD PHARMACEUTICAL CO., LTD. has occupied an important position in the global pharmaceutical industry since its establishment in 2009. The company is committed to the innovation and application of pharmaceutical technology. It is a modern pharmaceutical enterprise dedicated to providing high-quality and high-standards pharmaceutical products and services to customers around the world.

Welcome to Zhuhai City, the "Pearl of the South China Sea", which is located next to Hong Kong and Macao, and is the central city of the Guangdong-Hong Kong-Macao Greater Bay Area with beautiful scenery and a very dynamic economy.